CD38 and chronic myelogenous leukemia, BCR-ABL1 positive: Regarding the LSC identification, in 2014 Hermann and colleagues identified the enzyme dipeptidyl-peptidase-IV (DPPIV/CD26) as a specific marker of the CD34+/CD38- leukemic progenitors, demonstrating in a murine model that these cells were able to summarize the CML onset and that they decreased remarkably during the successful treatment with imatinib (13).